TD-HV612036

Mirzotamab(TD-HV612036) is a research-grade recombinant antibody targetingCD276. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Monoclonal

CD276, B7-H3, Costimulatory molecule, B7H3, 4Ig-B7-H3, B7 homolog 3, CD276 antigen

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q5ZPR3

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

ABBV-155, 2229859-11-2

Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.

SEC-HPLC detection for Research Grade Mirzotamab.　　|　Detects CD276/B7-H3 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Mirzotamab.　　|　Flow-cytometry using APC anti-human CD276 antibody. PC-3 cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD276 monoclonal antibody (Catalog: HV612036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer. ### Flow-cytometry using FITC anti-human CD276 antibody. PC-3 cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD276 monoclonal antibody (Catalog: HV612036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer. ### Flow-cytometry using PE anti-human CD276 antibody. PC-3 cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CD276 monoclonal antibody (Catalog: HV612036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.　　|　Western blot analysis was performed using anti-CD276 monoclonal antibody at 1μg/ml on various samples.Lane 1:recombinant human CD276 (Catalog No:TD-HV612011)

For research use only. Not suitable for clinical or therapeutic use.